Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMED Study: Sacituzumab Govitecan Tolerance in Metastatic Triple-Negative Breast Cancer
2022-001397-61Phase 2Active
- Sponsor
- MEDSIR
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in breast cancer, sponsored by MEDSIR. Primary endpoints: Incidence of grade ≥2 diarrhea at cycle and Incidence of neutropenia. Started Jul 2022; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-001397-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001397-61.